Inhalation Sciences Sweden AB (ISAB) has received service orders valued at EUR 58,525 (approximately SEK 646,000) from two recurring clients - a global pharmaceutical company and a leading global generic drug manufacturer.
The clients, who have been customers of ISAB for many years, continue to use ISAB's inhalation research instruments on a regular basis and have consistently expressed strong satisfaction with the performance and reliability of ISAB's technology.
Manoush Masarrat, CEO of Inhalation Sciences, comments:
"We are very pleased to once again be entrusted with orders from longstanding global clients. Their continued use of our systems underscores the quality and scientific value our instruments provide to leading pharmaceutical research. We look forward to supporting their projects and contributing to their long-term success in inhalation development."
For more information, please contact:
Manoush Masarrat, CEO
Phone: +46 (0) 73 628 9153
E-mail: manoush.masarrat@inhalation.se
About Inhalation Sciences Sweden AB (publ)
Inhalation Sciences is a cutting-edge Contract Research Organization (CRO) specializing in inhalation drug development. Leveraging our proprietary technology platform, PreciseInhale®, we empower our clients to de-risk and accelerate their R&D pipelines by delivering high-resolution, predictive data early in the development process.